Zuzana J. Berrong

Zuzana J. Berrong

Auto-generated profile, based on publicly available information

Zuzana J. Berrong

Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2021 in Immunity
Verified
Journal Article
Closed access
MSMadhav D. Sharma
Madhav D. Sharma
RPRafal Pacholczyk
Rafal Pacholczyk
HSHuidong Shi
Huidong Shi
ZBZuzana J. Berrong
Zuzana J. Berrong
YZYousef Zakharia
Yousef Zakharia
DMDavid H. Munn
David H. Munn

2 July 2014 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
CWCharles C. Weige
Charles C. Weige
MBMarc R. Birtwistle
Marc R. Birtwistle
HMHimel Mallick
Himel Mallick
NYNengjun Yi
Nengjun Yi
ZBZuzana Berrong
Zuzana Berrong
PBPhillip J. Buckhaults
Phillip J. Buckhaults
African Americans are disproportionately affected by early-onset, high-grade malignancies. A fraction of this cancer health disparity can be explained by genetic differences between individuals of African or European descent. Here the wild-type Pro/Pro genotype at the TP53Pro72Arg (P72R) polymorphism (SNP: rs1042522) is more frequent in African Americans with cancer than in African Americans without cancer (51% vs. 37%), and is associated with a significant increase in the rates of cancer diagnosis in African Americans. To test the hypothesis that Tp53 allele–specific gene expression may contribute to African American cancer disparities, TP53 hemizygous knockout variants were generated and characterized in the RKO colon carcinoma cell line, which is wild type for TP53 and heterozygous at the TP53Pro72Arg locus. Transcriptome profiling, using RNAseq, in response to the DNA-damaging agent etoposide revealed a large number of Tp53-regulated transcripts, but also a subset of transcripts that were TP53Pro72Arg allele specific. In addition, a shRNA-library suppressor screen for Tp53 allele–specific escape from Tp53-induced arrest was performed. Several novel RNAi suppressors of Tp53 were identified, one of which, PRDM1β (BLIMP-1), was confirmed to be an Arg-specific transcript. Prdm1β silences target genes by recruiting H3K9 trimethyl (H3K9me3) repressive chromatin marks, and is necessary for stem cell differentiation. These results reveal a novel model for African American cancer disparity, in which the TP53 codon 72 allele influences lifetime cancer risk by driving damaged cells to differentiation through an epigenetic mechanism involving gene silencing. Implications: TP53 P72R polymorphism significantly contributes to increased African American cancer disparity. Mol Cancer Res; 12(7); 1029–41. ©2014 AACR.